Florida Eye Institute cataract surgeons Karen Todd, MD and Val Zudans, MD, have successfully demonstrated the technical knowledge to implant the Hydrus Microstent according to certification by Richard Hope, MD, Vice President of Clinical and Medical Affairs at Ivantis.
Hydrus is the latest FDA approved minimally invasive glaucoma surgery (MIGS) device used for the treatment of mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.
“The Hydrus Microstent has proven to be a reliable option to reduce dependence on pressure lowering drops for our glaucoma patients,” states Karen Todd, MD, Board Certified Ophthalmologist, fellowship trained in glaucoma.
“We have searched a long time for the right minimally invasive, effective solution for open-angle glaucoma patients. Hydrus provides a convenient way to achieve two extremely positive outcomes with one surgery – removal of cataract and reduction of intra-ocular pressure.”
Dr. Val Zudans, Board Certified Ophthalmologist, cataract and refractive surgeon adds, “We are really impressed with the clinical findings. Recent studies show nearly 78% of Hydrus patients achieved a statistically significant decrease (≥ 20 percent reduction in unmedicated IOP) at 24-months postoperative. This represents the largest improvement over a control group in any MIGS trial to date.”
There are several options available for open-angle glaucoma. Current therapies include prescription eye drops, laser therapy, and surgery. Based on the severity of glaucoma and other health conditions, your ophthalmologist will recommend treatments for your specific needs.
To learn more about the latest developments in cataract surgery, glaucoma, and eye health visit fleye.com. Florida Eye Institute is located at 2750 Indian River Blvd. in Vero Beach and 13397 US Hwy 1 in Sebastian. Contact 772.569-9500 for more information.